Abstract Series of 1-[2-thiazol-4-yl-(2-aminoethyl)]-and 1-[2-thiazol-5-yl-(2-aminoethyl)]-4-n-propylpiperazine derivatives have been prepared and in vitro tested as H 3 -receptor antagonists (the electrically evoked contraction of the guineapig jejunum). It appeared that by comparison of homologous pairs, the 1-[2-thiazol-5-yl-(2-aminoethyl)]-4-n-propylpiperazines (3a,b and 4a-d) have much higher potency than their analogous 1-[2-thiazol-4-yl-(2-aminoethyl)]-4-n-propylpiperazines (2a-k). Based on the obtained results, we observed the 5-position of 2-methyl-2-R-aminoethyl substituents in the thiazole ring is favourable for histamine H 3 receptor antagonist activity, whereas its presence in position 4 leads, almost in each case, to strong decrease of activity.
Introduction
Histamine plays a variety of physiological roles in the central nervous system (CNS) and peripheral tissues through the four known G protein-coupled receptors, H 1 , H 2 , H 3 and H 4 (Hough, 2001) . H 1 and H 2 receptor antagonists are well-known therapeutic agents and are in use for the treatment of allergic disease (Leurs et al., 2002) and peptic ulcer (Brimblecombe et al., 1978) , respectively. The newly discovered H 4 receptor seems to have a role in regulating inflammatory responses (Thurmond et al., 2004) .
The histamine H 3 receptor, which was discovered in 1983 by Arrang and co-workers (Arrang et al., 1983) , mainly located in the CNS, is a presynaptic autoreceptor that does not only modulate the production and the release of histamine from histaminergic neurons (Arrang et al., 1987) but also regulates the release of other neurotransmitters like acetylocholine (Clapham and Kilpatrick, 1992; Yokatoni et al., 2000) , dopamine (Schlicker et al., 1993) , norepinephrine (Schlicker et al., 1990) , serotonin (Schlicker et al., 1988) and glutamate (Brown and Reymann, 1996) in both the CNS and peripheral nervous system. Enhancement of neurotransmitter release by histamine H 3 receptor antagonist shows a clinical approach to the treatment of several CNS disorders (Esbenshade et al., 2006; Cemkov et al., 2009) , including attention deficit hyperactivity disorder (Quades, 1987) , sleep disorders (Monti, 1993) , epilepsy (Vahora et al., 2001) and schizophrenia (Velligan and Miller, 1999) . Pharmacological data also suggest a potential role for H 3 antagonists in the control of feeding, appetite, and support the role of H 3 receptor in obesity (Hancock, 2003; Hancock et al., 2004) .
Early generation of H 3 receptor ligands were based on structures containing the imidazole moiety, many of which have found utility as pharmacological tools (Stark et al., 1996; Van der Goot and Timmerman, 2000) . However, antagonist carrying on the imidazole heterocycle is the potential issue for drug-drug interactions through inhibition of hepatic cytochrome P 450 enzymes and poor CNS penetration (Lin and Lu, 1998; Zhang et al., 2005) . For these reasons, and after the successful cloning of the human histamine H 3 receptor by Lovenberg (Lovenberg et al., 1999) , efforts have been directed towards the discovery of H 3 antagonists without an imidazole moiety as these compounds may offer improvements in binding affinity, CNS penetration, and reduced potential for cytochrome P 450 enzymes inhibition (Cowart et al., 2004) . A number of nonimidazole antagonists have since been reported (Ganellin et al., 1998; Celanire et al., 2005) . Representative examples of non-imidazole H 3 antagonists included among others were JNJ-5207852 (hH 3 RK i = 0.6 nM) (Apodaca et al., 2003) , UCL 2190 (rH 3 RK i = 4 nM) (Meier et al., 2001) and ABT-239 (hH 3 RK i = 0.45 nM) (Cowart et al., 2002) (Chart 1).
Previously, our laboratory has described several non-imidazole piperazine-based histamine H 3 antagonists, consisting of 1-(2-thiazolobenzo)-, 1-(2-thiazolopyridine)-and 1-[2-thiazol-5-yl-(2-aminoethyl)] moieties with moderate to pronounced affinity for the receptor (Walczyński et al., 1999 (Walczyński et al., , 2005 Frymarkiewicz and Walczynski, 2009) 
UCL2190
The target molecules of this study (Walczyński et al., 1999 (Walczyński et al., , 2005 . These results prompted us to replace the benzo ring by 2-methyl-2-alkylaminoethyl amide, 2-methyl-2-alkylaminoethyl and 2-methyl-2-phenylalkylaminoethyl chains at position 5 of 1-(2-thiazol-5-yl)-4-n-propylpiperazine moiety. The highest affinity for these series has been seen in the compound with the N-methyl-N-phenylpropylamino substituent 1 (Chart 1; pA 2 = 8.27; electric field stimulation assay on guinea-pig jejunum) and with slightly lower potencies for compounds carrying on N-methyl-N-benzylamino and N,N-dimethylamino substituents with pA 2 = 7. 75 and 7.78, respectively (Frymarkiewicz and Walczynski, 2009 ). In continuation of our earlier work, we studied the influence, on H 3 -receptor antagonistic activity, of the introduction of 2-CH 3 -2-R-aminoethyl-substitution at position 4 of the thiazole ring. Therefore, the series of 1-[2-thiazol-4-yl-(2-aminoethyl)]-4-n-propylpiperazines 2a-k (Chart 1), bearing the substituents showing the highest affinity in previously described 1-[2-thiazol-5-yl-(2-aminoethyl)]-4-n-propylpiperazines (Frymarkiewicz and Walczynski, 2009) , was prepared and pharmacologically evaluated (electric field stimulation assay on guinea-pig jejunum). In addition, with the aim of the complement 1-[2-thiazol-5-yl-(2-aminoethyl)]-4-n-propylpiperazines series, 1-[2-thiazol-5-y l-(2-methyl-2-phenylethyl)]-3a, 1-[2-thiazol-5-yl-(2-methy l-2-phenylbutylaminoethyl)]-4-n-propylpiperazine 3b and 1-[2-thiazol-5-yl-(2-methyl-2-phenylcarbonylaminoethyl)]-4-npropylpiperazine amides 4a-d (Chart 1) were synthesized.
In this study, we report on synthesis and preliminary pharmacological investigation of new 1-[2-thiazol-5-yl- RCOCl NaHCO 3 / DME 10 2e-g 2h-k for n=3,4,5
(2-aminoethyl)]-4-n-propylpiperazine derivatives 2 and 1-[2-thiazol-5-yl-(2-methyl-2-phenylethyl-, 1-[2-thiazol-5-yl-(2-methyl-2-phenylbutylaminoethyl)]-4-n-propylpiperazines 3 and 1-[2-thiazol-5-yl-(2-methyl-2-phenylcarbonylaminoethyl)]-4-n-propylpiperazine amides 4.
Chemistry
The general synthetic procedure used in this study is illustrated in Schemes 1 and 2. 1-[2-Thiazol-4-yl-(2-methylaminoethyl)]-4-n-propylpiperazine 10 (Scheme 1) was prepared from compound 5 by four-step synthesis including cyclization reaction of 1-(4-n-propyl)piperazine thioamide 5 with ethyl 4-chloroacetoacetate 6 to 1-[2-thiazol-4-yl-(2-methoxycarbonylethyl)]-4-n-propylpiperazine 7, reduction with LiAlH 4 in dry ethyl ether to 1-[2-thiazol-4-yl-(2-hydroxyethyl)]-4-n-propylpiperazine 8, mesylation with methanesulfonyl chloride in dry pyridine to 1-[2-thiazol-4-yl-(2-mesyloxyethyl)]-4-n-propylpiperazine 9 and finally through nucleophilic displacement of the mesyloxy group by methylamine in methanol to 1-[2-thiazol-4-yl-(2-methylaminoethyl)]-4-n-propylpiperazine 10. 1-[2-Thiazol-4-yl-(2-methy-2-alkylaminoethyl)]-4-n-propylpiperazines 2a,b and 1-[2-thiazol-4-yl-(2-methy-2-phenylalkylaminoethyl)]-4-npropylpiperazines 2c,d were prepared from 1-[2-thiazol-4-yl-(2-mesyloxyethyl)]-4-n-propylpiperazine 9 through nucleophilic substitution of the mesyloxy group by an appropriate secondary amine in methanol. Compounds 2e-g, 1-[2-thiazol-4-yl-(2-methyl-2-phenylalkylaminoethyl)]-4-n-propylpiperazine, were obtained from 1-[2-thiazol-4-y l-(2-methylaminoethyl)]-4-n-propylpiperazine 10 by alkylation with the corresponding primary phenyloalkyl halides in acetonitrile followed by purification with column chromatography. [2-Thiazol-4-yl-(2-metyl-2-phenylcarbonylaminoethyl)]-4-n-propylpiperazine amides 2h-k were obtained by standard methods. Compound 10 was acetylated with an appropriate acid chloride in the presence of NaHCO 3 in DME, followed by purification with column chromatography.
Compounds 3a, b, 1-[2-thiazol-5-yl-(2-methyl-2-phenylalkylaminoethyl)]-4-n-propylpiperazine (Scheme 2), were synthesized from compound 11 by alkylation with the corresponding primary phenylalkyl halides in acetonitrile followed by purification with column chromatography. Amides 4a-d were obtained by acetylation of 1-[2-thiazol-5-yl-(2-methylaminoethyl)]-4-n-propylpiperazine 11 (Scheme 2) with an Scheme 2 Synthesis of 1-[2-thiazol-5-yl-(2-methyl-2-phenylalkylaminoethyl)]-4-npropyl-piperazines 3a, b and 1-[2-thiazol-5-yl-(2-methyl-2-phenylcarbonylaminoethyl)]-4-n-propyl-piperazine amides 4a-d
Med Chem Res (2013) 22:3640-3652 3643 appropriate acid chloride with the presence of K 2 CO 3 in DME, followed by purification with column chromatography. All free bases were dissolved in small amount of n-propanol and treated with methanolic HBr. The hydrobromides crystallized as white solid.
The 1-(4-n-propyl)piperazine thioamide (5) was directly obtained by the reaction of the 1-n-propylpiperazine dihydrobromide with potassium thiocyanate in aqueous solution (Frymarkiewicz and Walczynski, 2009 ).
The 5-phenylpentyl bromide was obtained according to Collins (Collins and Davis, 1961) . The 5-phenyl-1-pentanol was converted into the bromide by treatment with 50 % aqueous hydrobromic acid and concentrated sulphuric acid.
The ethyl 4-chloroacetoacetate, 1-n-propylpiperazine dihydrobromide, benzyl bromide, 1-bromo-3-phenylpropane, 1-bromo-4-phenylbutane 5-phenyl-1-pentanol, dimethylamine solution in methanol, N-methylpropylamine, N-benzylmethylamine, N-methyl-2-phenethylamine, benzoyl chloride, p-toluoyl chloride, 4-chlorobenzoyl chloride and 4-nitrobenzoyl chloride were all purchased from commercial sources.
Results and discussion
The compounds were in vitro tested as H 3 receptor antagoniststhe electrically evoked contraction of the guinea-pig jejunum.
The presented series of 1-[2-thiazol-4-yl-(2-aminoethyl)]-4-n-propylpiperazines (2a-k) and their analogous 1-[2-thiazol-5-yl-(2-aminoethyl)]-4-n-propylpiperazine (3a,b and 4a-d) derivatives possess weak to pronounced H 3 -receptor antagonist potency (Table 1) .
The introduction of 2-methyl-2-R-aminoethyl-substituents at position 4 of the thiazole ring led to the derivatives 2a, b, d-k having, independent of the sort of substituent, weak activity, except for derivative 2c showing moderate affinity with pA 2 = 7.12.
It appeared that by comparison of homologous pairs,the 1-[2-thiazol-5-yl-(2-aminoethyl)]-4-n-propylpiperazines (3a,b and 4a-d) have much higher potency than their analogous 1-[2-thiazol-4-yl-(2-aminoethyl)]-4-n-propylpiperazines (2a-k). The differences are observed inside of each series. In the case of 1-[2-thiazol-4-yl-(2-aminoethyl)]-4-n-propylpiperazines, 
Thioperamide-pA 2 H 3 = 8.43, (sem) (0.07); N (caviae)-18 (6) H 3 antagonistic activity of all compounds marked with asterisk was described in previous paper (Frymarkiewicz and Walczynski, 2009) sem standard error of the mean, N number of different animal preparation; cavie number of animals; m and n number of HBr elongation of alkyl chain from one to three methylene groups results in an increase of potency for 2a pA 2 = 6.76 and 2b pA 2 = 6.96, this is in opposition to the 1-[2-thiazol-5-yl-(2-aminoethyl)]-4-n-propylpiperazine derivatives where the 1-[2-thiazol-5-yl-(2-N,N-dimethylaminoethyl)]-4-n-propylpiperazine shows slightly higher potency than its N-methyl-N-propyl analogue (pA 2 = 7.78; pA 2 = 7.53, respectively).
In the 2-methyl-2-phenylalkyl derivatives of 1-[2-thiazol-4-yl-(2-aminoethyl)]-4-n-propylpiperazine (2c-g), there is no significant difference in affinity. Elongation of alkyl chain from one to five methylene groups does not influence antagonistic activity (pA 2 ranging from 6.81 for compound 2d to 6.69 for compound 2g). In the analogues series, there is no significant difference in affinity among the methyl and ethyl derivatives (pA 2 = 7.76 and 7.61 for compound 3a). A further elongation in the alkyl chain length to 3 methylene groups results in an increase of antagonistic activity, reaching the maximum for 1-[2-thiazol-5-yl-(2-methyl-2-phenylpropylaminoethyl)]-4-n-propylpiperazine (pA 2 = 8.27); activity decreases on further lengthening up to 5 methylene groups (pA 2 = 7.80 for compound 3b and 7.25 for 1-[2-thiazol-5-yl-(2-phenylpentylmethylaminoethyl)]-4-n-propylpiperazine). Replacement of hydrogen by p-benzoyl substituent at the end of N-methyl group leads to the compounds 2h-k (pA 2 from 5.65 to 6.23) and their analogues 4a-d (pA 2 from 7.45 to 7.76). By comparison of homologous pairs, the 1-[2-thiazol-5-yl-(2-methyl-2-phenylcarbonylaminoethyl)]-4-n-propylpiperazineamides 4a-d have much higher potency than their analogous 1-[2-thiazol-4-yl-(2-methyl-2-phenylcarbonylaminoethyl)]-4-n-propylpiperazine amides 2h-k. In both series, a slightly higher activity is observed for compounds carrying on electron-withdrawing substituent at para-position in the benzene ring.
Summarizing, 1-[2-thiazol-5-yl-(2-aminoethyl)]-4-n-propylpiperazines display a higher activity than their 1-[2-thiazol-4-yl-(2-aminoethyl)]-4-n-propylpiperazine analogues. We observe that the position 5 of 2-methyl-2-R-aminoethyl-substituents in the thiazole ring is favourable for histamine H 3 receptor antagonist activity, whereas its presence in position 4 leads, almost in each case, to strong decrease of activity.
The highest potency for both homologous series is seen in the compound with the 2-methyl-2-phenylpropylaminoethyl substituent (pA 2 = 8.27) and with slightly lower potencies for compounds carrying on 2,2-dimethylaminoethyl, 2-methyl-2-(4-chlorophenyl)carbonylaminoethyl and 2-methyl-2-(4-nitrophenyl)-carbonylaminoethyl substituents (pA 2 = 7.78; pA 2 = 7.73 and pA 2 = 7.76, respectively).
Experimental protocols
General Methods. All melting points (mp) were measured in open capillaries on an electrothermal apparatus and are uncorrected. For all compounds, 1 H NMR spectra were recorded on a Varian Mercury 300 MHz spectrometer. Chemical shifts are expressed in ppm downfield from internal TMS as reference.
1 H NMR data are reported in order: multiplicity (br, broad; s, singlet; d, doublet; t, triplet; m, multiplet; * exchangeable by D 2 O) number of protons, and approximate coupling constant in Hertz.
13 C NMR spectra were recorded on Bruker Avance III 600 MHz spectrometer. Elemental analysis (C, H, N) for all compounds were measured on Perkin Elmer Series II CHNS/O Analyzer 2400 and are within ±0.4 % of the theoretical values. TLC was performed on silica gel 60 F 254 plates (Merck). Flash column chromatography was carried out using silica gel 60 Å 50 lm (J. T. Baker B. V.), employing the same eluent as was indicated by TLC.
Chemistry
The synthesis of 1-[2-thiazol-4-yl-(2-methoxycarbonylethyl)]-4-n-propylpiperazine (7) The 1-(4-n-propyl)piperazine thioamide (5) (0.032 mol) was added to a solution of ethyl 4-chloroacetoacetate (6) (0.032 mol) in 70 mL of n-propanol. The reaction mixture was heated at 90°C for 6 h. After cooling, the solvent was removed in vacuo. The hydrochloride product was obtained as brown solid. The free base was obtained as follows: the hydrochloride of the 1-[2-thiazol-4-yl-(2-methoxycarbonylethyl)]-4-n-propylpiperazine (7) was mixed with saturated aqueous sodium bicarbonate solution for 1 h at room temperature and then water layer was extracted with dichloromethane (2 9 30 mL). The organic extracts were washed with water (3 9 30 mL), dried (Na 2 SO 4 ), filtered and evaporated to give compound 7 as a sticky oil: The free base was dissolved in small amount of n-propanol and treated with methanolic HBr. The dihydrobromide crystallized as white solid. The synthesis of 1-[2-thiazol-4-yl-(2-hydroxyethyl)]-4-n-propylpiperazine (8) To a solution of the 1-[2-thiazol-4-yl-(2-methoxycarbonylethyl)]-4-n-propylpiperazine (7) (0.032 mol) in 110 mL of DME at 55°C, LiBH 4 (0.055 mol) was added. The mixture was stirred at 70°C for 24 h. The solvent was evaporated and remaining material was dissolved in 60 mL of methanol and was heated at 70°C for 24 h. The solvent was evaporated and the residue was purified by column chromatography on silica gel. The title products were obtained as sticky oil. The free base was dissolved in small amount of n-propanol and treated with methanolic HBr. The dihydrobromide crystallized as white solid. The synthesis of 1-[2-thiazol-4-yl-(2-mesyloxyethyl)]-4-npropylpiperazine (9)
To a cooled solution of the 1-[2-thiazol-4-yl-(2-hydroxyethyl)]-4-n-propylpiperazine (8) (0.009 mol) in 10 mL of dry pyridine, while stirring, methanesulfonyl chloride (0.009 mol) was added dropwise. The mixture was stirred at room temperature for 0.5 h. Then, reaction mixture was poured out in ice-cold water (40 mL) and extracted with ethyl ether (3 9 50 mL). The combined organic extracts were dried (Na 2 SO 4 ), filtered and evaporated to give compound 9 as a sticky yellow oil. The crude compound 9 was used in the next step without further purification. CH 3 SO 3 CH 2 , J = 6.6 Hz) 6,29 (s, 1H, H thiazole ); TLC (methylen chloride:methanol 10:1) R f = 0.44.
The synthesis of 1-[2-thiazol-4-yl-(2-methylaminoethyl)]-4-n-propylpiperazine (10)
The crude 1-[2-thiazol-4-yl-(2-mesyloxyethyl)]-4-n-propylpiperazine 9 (0.008 mol) was dissolved in 30 mL of 40 % solution methylamine in methanol. The mixture was stirred at room temperature for 24 h. Then, organic solvent was evaporated, and residue was dissolved in DME (40 mL), alkalized with solid NaHCO 3 (0.001 mol) and stirred for 1 h. The mixture was filtered and DME was evaporated to give compound 2 as a yellowish sticky oil. The free base was dissolved in small amount of n-propanol and treated with methanolic HBr. The treehydrobromide crystallized as white solid. 
General method for the preparation of 1-[2-thiazol -4-yl-(2-alkylmethylaminoethyl)] (2a,b) and 1-[2-thiazol-4-yl-(2-phenylalkylmethylaminoethyl)] 4-n -propylpiperazines (2c,d)
To a solution of 1-[2-thiazol-4-yl-(2-mesyloxyethyl)]-4-npropylpiperazine (9) (0.002 mol) in 5.0 mL of methanol, the corresponding amine (0.004 mol) was added (in case of the compound 2a-33 % solution dimethylamine in methanol was used). The mixture was stirred at 50°C for 6-10 h. (monitored by TLC). After the completion of reaction, the solvent was evaporated and the residue was alkalized with saturated aqueous NaHCO 3 solution (15 mL) and stirred for 0.5 h. Then, the mixture was extracted with ethyl ether (3 9 30 mL). The combined organic extracts were dried (Na 2 SO 4 ), filtered and evaporated. The residue was purified by column chromatography on silica gel. The title products were obtained as sticky oil. 3428, 3073, 2963, 2923, 2708, 2655, 2581, 2527, 2469, 1611, 1591, 1459, 1426, 1356, 1289, 1239, 1181, 1133, 1099, 1055, 1028, 967, 898, 808, 760, 721, 638, 548 2963, 2918, 2702, 2653, 2579, 2459, 1615, 1429, 1287, 1185, 1097, 1056, 969, 751, 699 2962, 2928, 2702, 2653, 2577, 2458, 1613, 1594, 1456, 1411, 1357, 1289, 1181, 1098, 1055, 968, 807, 751, 698 . To a solution of 1-[2-thiazol-4-yl-(2-methylaminoethyl)]-4-n-propylpiperazine (10) (0.002 mol) or 1-[2-thiazol-5-yl-(2-methylaminoethyl)]-4-n-propylpiperazine (11) (0.002 mol) with the presence of K 2 CO 3 (0.003 mol) in 5.0 mL of acetonitrile, the corresponding phenylalkyl bromide (0.002 mol) was added. The mixture was stirred at room temperature for 6-10 h (monitored by TLC). Then, inorganic salt was filtered off and solvent was evaporated. The residue was purified by column chromatography on silica gel. The title products were obtained as sticky oil. The free base was dissolved in small amount of n-propanol and treated with methanolic HBr. The hydrobromide crystallized as white solid to give compounds 2e-g and 3a,b, respectively. 2962, 2922, 2649, 2577, 2519, 2458, 2363, 1620, 1453, 1430, 1403, 1286, 1240, 1185, 1134, 1033, 967, 808, 753, 3523, 3422, 3067, 2965, 2938, 2705, 2655, 2582, 2529, 2469, 1613, 1592, 1457, 1413, 1357, 1289, 1182, 1097, 1029, 969, 809, 748, 705, 669, 550 3077, 2937, 2876, 2653, 2580, 2458, 1616, 1597, 1434, 1286, 1185, 1096, 967, 807, 756, 701, 528 3052, 2959, 2915, 2695, 2583, 2526, 1578, 1430, 1409, 1309, 1291, 1243, 1188, 1161, 1093, 1033, 964, 810, 756, 728, 703, 623, 544, 510 . 3471, 3399, 3052, 2938, 2639, 2597, 2473, 1627, 1498, 1434, 1291, 1193, 1027, 964, 846, 752, 722, 597. General method for the preparation of 1-[2-thiazol-4-yl-(2-methyl-2-phenylcarbonylaminoethyl)]-4-npropylpiperazine amides 2h-k and 1-[2-thiazol-5-yl-(2-methyl-2-phenylcarbonylaminoethyl)]-4-npropylpiperazine amides 4a-d
To a solution of 1-[2-thiazol-4-yl-(2-methylaminoethyl)]-4-n-propylpiperazine (2) or 1-[2-thiazol-5-yl-(2-methylaminoethyl)]-4-n-propylpiperazine (11) (0.001 mol) in 10 mL of DME, the corresponding acid chloride (0.001 mol) was added. After 15 min, NaHCO 3 (0.001 mol) was added and the mixture was stirred at room temperature for 24 h. The solvent was evaporated and the residue was suspended with H 2 O (30 mL) and extracted with chloroform (3 9 30 mL). The combined organic extracts were dried (Na 2 SO 4 ), filtered and evaporated. The residue was purified by column chromatography on silica gel. The title products were obtained as sticky oil. The free base was dissolved in small amount of n-propanol and treated with methanolic HBr. The hydrobromide crystallized as white solid to give compounds 2h-k and 4a-d, respectively. Because 1 H NMR data for compounds 2h-k and 4a-d have been illegible.
13
C NMR data are presented for these derivatives.
2h. C 20 H 28 N 4 OS (M = 372); yield 82.9 %; (d in ppm; CDCl 3 , 600 MHz); 171.67; 161.18; 159.80; 137.06; 129.94; 128.00; 127.15; 122.37; 59.28; 52.05; 45.42; 43.59; 33.16; 27.08; 20.46; 13.29; . TLC (dichloromethane: methanol: 10:1) R f = 0,36.
IR (for dihydrobromide; KBr) cm -1 : 3399, 3104, 3077, 2974, 2919, 2793, 2919, 2793, 2703, 2664, 2576, 2465, 1599, 1501, 1439, 1406, 1275, 1218, 1187, 1122, 1072, 1029, 998, 967, 841, 798, 723, 637, 566, 463 171.53; 161.18; 159.80; 139.83; 133.26; 128.69; 126.73; 121.78; 60.08; 52.05; 46.07; 44.05; 33.09; 28.34; 21.50; 20.46; 13.29; .TLC (dichloromethane: methanol: 10:1) R f = 0.28.
IR (for dihydrobromide; KBr) cm -1 : 3431, 3102, 3000, 2926, 2768, 2569, 2514, 2462, 1597, 1478, 1455, 1406, 1362, 1291, 1276, 1184, 1122, 1075, 998, 967, 834, 786, 715, 640, 565, 476 3101, 3072, 2967, 2928, 2759, 2706, 2574, 2463, 1617, 1596, 1441, 1408, 1291, 1215, 1186, 1122, 1093, 1073, 1014, 965, 915, 845, 786, 757, 691, 670, 639, 553, 474 171.98; 161.57; 159.87 148.38; 143.12; 127.64; 123.71; 121.87; 55.24; 45.42; 43.81; 33.25; 27.89; 20.53; 13.32 ; TLC (dichloromethane: methanol: 10:1) R f = 0.43. IR (for dihydrobromide; KBr) cm -1 : 3430, 3102, 1620, 1597, 1522, 1439, 1410, 1352, 1290, 1179, 1073, 1031, 965, 869, 851, 747, 723, 639, 558, 457 87; 159.28; 138.48; 131.10; 130.04; 128.00; 126.46; 120.54; 56.47; 51.26; 45.44; 39.64; 32.76; 26.28; 20.49; 13.29; .TLC (dichloromethane:methanol: 19:1) R f = 0.32.
IR (for dihydrobromide monohydrate; KBr) cm -1 : 3509, 3436, 3046, 2971, 2923, 2681, 2586, 2522, 2464, 2084, 1629, 1607, 1575, 1443, 1402, 1360, 1294, 1221, 1098, 1075, 1023, 969, 794, 743, 714, 631, 546 172.67; 159.80; 140.06; 138.48; 128.32; 125.97; 120.45; 56.39; 51.34; 45.42; 39.75; 32.84; 26.16; 21.50; 20.46; 13.29; TLC (dichloromethane: methanol: concentrated ammonium hydroxide 89:10:1) R f = 0.51. IR (for dihydrobromide; KBr) cm 3430, 3079, 2967, 2920, 2637, 2564, 2452, 1611, 1479, 1437, 1400, 1285, 1270, 1199, 1068, 1039, 968, 925, 873, 839, 757, 726, 583, 508 172.87; 159.28; 138.53; 136.18 129.26; 128.96; 127.53; 120.00; 56.39; 51.23; 45.57; 39.61; 32.82; 26.25; 20.52; 13.30; TLC (dichloromethane: methanol: concentrated ammonium hydroxide 89:10:1) R f = 0.74 IR (for dihydrobromide; KBr) cm -1 : 3522, 3422, 3034, 2988; 2938, 2896, 2656, 2569, 2458, 1622, 1430, 1399, 1339, 1291, 1257, 1174, 1089, 1039, 968, 832, 793, 758, 728, 682, 600, 552, 480 172.98; 159.67; 148.27; 140.43; 138.48; 126.87; 123.71; 120.51; 56.42; 51.56; 45.48; 39.81; 32.76; 26.22; 20.51; 13.32 ; TLC (dichloromethane: methanol: 10:1) R f = 0.43.
IR (for dihydrobromide monohydrate; KBr) cm -1 : 3451, 3039, 2968, 2934, 2903, 2784, 2696, 2601, 2515, 2457, 1625, 1599, 1524, 1445, 1429, 1404, 1353, 1290, 1260, 1176, 1095, 1033, 1009, 968, 870, 742, 725 Pharmacology All compounds were tested for H 3 antagonistic effects in vitro on the guinea-pig jejunum using standard methods (Vollinga et al., 1992) . Male guinea pigs weighing 300-400 g were killed by a blow on the head. A portion of the small intestine, 20-50 cm proximal to the ileocaecal valve (jejunum), was removed and placed in Krebs buffer (composition (mM) NaCl 118; KCl 5.6; MgSO 4 1.18; CaCl 2 2.5; NaH 2 PO 4 1.28; NaHCO 3 25; glucose 5.5 and indomethacin (1 9 10 -6 mol/L)). Whole jejunum segments (2 cm) were prepared and mounted between two platinum electrodes (4 mm apart) in 20 mL Krebs buffer, continuously gassed with 95 % O 2 :5 % CO 2 and maintained at 37°C. Contractions were recorded isotonically under 1.0 g tension with Hugo Sachs Hebel-Messvorsatz (Tl-2)/HF-modem (Hugo Sachs Electronik, Hugstetten, Germany) connected to a pen recorder. After equilibration for 1 h with every 10 min washings, the muscle segments were stimulated maximally between 15 and 20 V and continuously at a frequency of 0.1 Hz and a duration of 0.5 ms, with rectangular-wave electrical pulses, delivered by a Grass Stimulator S-88 (Grass Instruments Co., Quincy, USA). After 30 min of stimulation, 5 min before adding (R)-a-methylhistamine, pyrilamine (1 9 10 -5 mol/L concentration in organ bath) was added, and then cumulative concentrationresponse curves (half-log increments) of (R)-a-methylhistamine, H 3 -agonist were recorded until no further change in response was found. Five minutes before adding the tested compounds, the pyrilamine (1 9 10 -5 mol/L concentration in organ bath) was added, and after 20 min cumulative concentration-response curves (half-log increments) of (R)-a-methylhistamine, H 3 -agonist, were recorded until no further change in response was found. Statistical analysis was carried out with the Students' t test. In all tests, p \ 0.05 was considered statistically significant. The potency of an antagonist is expressed by its pA 2 value calculated from the Schild (Arunlakshana and Schild, 1959) regression analysis where at least three concentrations were used. The pA 2 values were compared with the potency of thioperamide.
